Results 211 to 220 of about 36,345 (262)

Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641. [PDF]

Transl Androl Urol
Nguyen MD, Vinh-Hung V, Verschraegen C, Wang P.   +3 more
europepmc   +1 more source

Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.

JAMA Netw Open
Büttner T, Klümper N, Ellinger J, Ritter M, Krausewitz P.   +4 more
europepmc   +1 more source

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]

Drugs Real World Outcomes
Bosch D, van der Velden KJM, Beeker A, van den Berg HP, Bergman AM, van der Doelen MJ, van den Eertwegh AJM, Hendriks MP, Kerkhofs TMA, van de Luijtgaarden ACM, Mehra N, van Moorselaar RJA, Tascilar M, Vervenne WL, Weijl NI, Uyl-de Groot CA, Mulders PFA, Kuppen MCP, van Oort IM.   +18 more
europepmc   +1 more source

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Graff JN, Smith CEP, Sokolova AO, Qian DZ, Beer TM, Latour E, Bailey S, Kreitner D, Grivas P, Schweizer MT, Higano CS, Alumkal JJ, Vuky J, Yu EY, Cheng HH.   +14 more
europepmc   +1 more source

Quercetin Inhibits AKT Ser473 Phosphorylation and Disrupts AKT-Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Cells. [PDF]

Antioxidants (Basel)
Duprat F, Azócar-Plaza S, Castillo-Cáceres MP, Rivas Y, Sanzana-Rosas J, Pampaloni P, Olivas-Henríquez G, Toledo J, Villa JL, Bertinat R, Jara N, Vallejos-Almirall A, Salas A, González-Chavarría I.   +13 more
europepmc   +1 more source

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB.   +29 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The hallmarks of castration-resistant prostate cancers

Cancer Treatment Reviews, 2015
Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan.
Palma Rocchi, Claudia Andrieu, Maria Katsogiannou   +2 more
exaly   +3 more sources

Steroidogenesis in castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations, 2023
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed.
Masaki Shiota, Satoshi Endo, Leandro Blas, Naohiro Fujimoto, Masatoshi Eto   +4 more
openaire   +2 more sources

Management of Patients with Castration-Resistant Disease

Hematology/Oncology Clinics of North America, 2013
The medical management of men with castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade. Men can now access several agents developed to extend survival, delay morbidity caused by complications, and preserve quality of life.
Carmel, Pezaro, Aurelius, Omlin, David, Lorente, Johann, de Bono   +3 more
openaire   +2 more sources